CYCCP

Cyclacel Pharmaceuticals (CYCCP)

Cyclacel Pharmaceuticals Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:CYCCP

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/06/04	21 : 00	GlobeNewswire Inc.	Cyclacel’s Fadraciclib Demonstrates Efficacy in Patient-Derived Colorectal Cancer Models at the 2024 ASCO Annual Meeting	NASDAQ:CYCCP	Cyclacel Pharmaceuticals Inc
2024/06/03	21 : 00	GlobeNewswire Inc.	Cyclacel Pharmaceuticals Reports New Clinical Data at 2024 ASCO Annual Meeting Highlighting Oral Fadraciclib’s Potential as a Precision Medicine for Cancer	NASDAQ:CYCCP	Cyclacel Pharmaceuticals Inc
2024/05/17	22 : 56	Edgar (US Regulatory)	Form D - Notice of Exempt Offering of Securities	NASDAQ:CYCCP	Cyclacel Pharmaceuticals Inc
2024/05/15	06 : 12	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:CYCCP	Cyclacel Pharmaceuticals Inc
2024/05/15	05 : 05	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CYCCP	Cyclacel Pharmaceuticals Inc
2024/05/15	05 : 05	GlobeNewswire Inc.	Cyclacel Pharmaceuticals Reports First Quarter Financial Results and Provides Business Update	NASDAQ:CYCCP	Cyclacel Pharmaceuticals Inc
2024/05/14	13 : 15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:CYCCP	Cyclacel Pharmaceuticals Inc
2024/05/14	05 : 05	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:CYCCP	Cyclacel Pharmaceuticals Inc
2024/05/08	22 : 15	GlobeNewswire Inc.	Cyclacel Pharmaceuticals to Release First Quarter 2024 Financial Results	NASDAQ:CYCCP	Cyclacel Pharmaceuticals Inc
2024/05/08	10 : 56	Edgar (US Regulatory)	Form ARS - Annual Report to Security Holders	NASDAQ:CYCCP	Cyclacel Pharmaceuticals Inc
2024/05/08	10 : 53	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:CYCCP	Cyclacel Pharmaceuticals Inc
2024/05/08	10 : 52	Edgar (US Regulatory)	Form DEF 14A - Other definitive proxy statements	NASDAQ:CYCCP	Cyclacel Pharmaceuticals Inc
2024/05/07	06 : 26	Edgar (US Regulatory)	Form S-1 - General form for registration of securities under the Securities Act of 1933	NASDAQ:CYCCP	Cyclacel Pharmaceuticals Inc
2024/05/03	05 : 30	GlobeNewswire Inc.	Cyclacel Pharmaceuticals Announces Closing of $8.0 Million Private Placement Priced At-The-Market Under NASDAQ Rules	NASDAQ:CYCCP	Cyclacel Pharmaceuticals Inc
2024/05/01	02 : 51	AllPennyStocks.com	$8 Million Private Placement Announcement Sends Biotech Flying	NASDAQ:CYCCP	Cyclacel Pharmaceuticals Inc
2024/04/30	20 : 00	GlobeNewswire Inc.	Cyclacel Pharmaceuticals Announces $8.0 Million Private Placement Priced At-The-Market Under Nasdaq Rules	NASDAQ:CYCCP	Cyclacel Pharmaceuticals Inc
2024/04/01	22 : 15	GlobeNewswire Inc.	Cyclacel Pharmaceuticals to Present New Clinical Data at 2024 ASCO Annual Meeting Highlighting Fadraciclib’s Potential as a Precision Medicine for Cancer	NASDAQ:CYCCP	Cyclacel Pharmaceuticals Inc
2024/03/20	05 : 05	GlobeNewswire Inc.	Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	NASDAQ:CYCCP	Cyclacel Pharmaceuticals Inc
2024/03/14	05 : 05	GlobeNewswire Inc.	Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2023 Financial Results	NASDAQ:CYCCP	Cyclacel Pharmaceuticals Inc
2024/03/07	23 : 15	GlobeNewswire Inc.	Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024	NASDAQ:CYCCP	Cyclacel Pharmaceuticals Inc
2024/03/06	23 : 15	GlobeNewswire Inc.	Cyclacel Pharmaceuticals Announces Receipt of $2.9 Million R&D Tax Credit	NASDAQ:CYCCP	Cyclacel Pharmaceuticals Inc
2024/02/20	23 : 15	GlobeNewswire Inc.	Cyclacel Pharmaceuticals to Participate in 2024 BIO CEO & Investor Conference	NASDAQ:CYCCP	Cyclacel Pharmaceuticals Inc
2024/02/15	06 : 31	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:CYCCP	Cyclacel Pharmaceuticals Inc
2024/02/15	06 : 06	Edgar (US Regulatory)	Form 424B3 - Prospectus [Rule 424(b)(3)]	NASDAQ:CYCCP	Cyclacel Pharmaceuticals Inc
2024/02/15	00 : 09	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:CYCCP	Cyclacel Pharmaceuticals Inc
2024/02/14	14 : 15	Edgar (US Regulatory)	Form EFFECT - Notice of Effectiveness	NASDAQ:CYCCP	Cyclacel Pharmaceuticals Inc
2024/02/14	05 : 47	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:CYCCP	Cyclacel Pharmaceuticals Inc
2024/02/08	07 : 03	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	NASDAQ:CYCCP	Cyclacel Pharmaceuticals Inc
2024/02/01	06 : 56	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NASDAQ:CYCCP	Cyclacel Pharmaceuticals Inc
2024/01/30	23 : 15	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:CYCCP	Cyclacel Pharmaceuticals Inc